Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
April 3, 2025

FDA grants fast track status to Biogen’s BIIB080 for Alzheimer’s

Biogen has received fast track designation from the US Food and Drug Administration (FDA) for its investigational antisense oligonucleotide (ASO) therapy, BIIB080, to treat Alzheimer's disease.

BIIB080 is the first tau-targeting ASO to enter clinical development for Alzheimer's disease. Credit: Steven HWG for Unsplash.